272 related articles for article (PubMed ID: 23697804)
1. Exploitation of bacterial N-linked glycosylation to develop a novel recombinant glycoconjugate vaccine against Francisella tularensis.
Cuccui J; Thomas RM; Moule MG; D'Elia RV; Laws TR; Mills DC; Williamson D; Atkins TP; Prior JL; Wren BW
Open Biol; 2013 May; 3(5):130002. PubMed ID: 23697804
[TBL] [Abstract][Full Text] [Related]
2. Outer membrane vesicles displaying engineered glycotopes elicit protective antibodies.
Chen L; Valentine JL; Huang CJ; Endicott CE; Moeller TD; Rasmussen JA; Fletcher JR; Boll JM; Rosenthal JA; Dobruchowska J; Wang Z; Heiss C; Azadi P; Putnam D; Trent MS; Jones BD; DeLisa MP
Proc Natl Acad Sci U S A; 2016 Jun; 113(26):E3609-18. PubMed ID: 27274048
[TBL] [Abstract][Full Text] [Related]
3. An O-Antigen Glycoconjugate Vaccine Produced Using Protein Glycan Coupling Technology Is Protective in an Inhalational Rat Model of Tularemia.
Marshall LE; Nelson M; Davies CH; Whelan AO; Jenner DC; Moule MG; Denman C; Cuccui J; Atkins TP; Wren BW; Prior JL
J Immunol Res; 2018; 2018():8087916. PubMed ID: 30622981
[TBL] [Abstract][Full Text] [Related]
4. Glycoconjugate vaccine using a genetically modified O antigen induces protective antibodies to
Stefanetti G; Okan N; Fink A; Gardner E; Kasper DL
Proc Natl Acad Sci U S A; 2019 Apr; 116(14):7062-7070. PubMed ID: 30872471
[No Abstract] [Full Text] [Related]
5. Is Pseudomonas aeruginosa exotoxin A a good carrier protein for conjugate vaccines?
Pier GB
Hum Vaccin; 2007; 3(2):39-40; author reply 41. PubMed ID: 17268204
[No Abstract] [Full Text] [Related]
6. Development of an automated platform for the optimal production of glycoconjugate vaccines expressed in Escherichia coli.
Samaras JJ; Mauri M; Kay EJ; Wren BW; Micheletti M
Microb Cell Fact; 2021 May; 20(1):104. PubMed ID: 34030723
[TBL] [Abstract][Full Text] [Related]
7. Hijacking bacterial glycosylation for the production of glycoconjugates, from vaccines to humanised glycoproteins.
Cuccui J; Wren B
J Pharm Pharmacol; 2015 Mar; 67(3):338-50. PubMed ID: 25244672
[TBL] [Abstract][Full Text] [Related]
8. First characterization of immunogenic conjugates of Vi negative Salmonella Typhi O-specific polysaccharides with rEPA protein for vaccine development.
Salman M; St Michael F; Ali A; Jabbar A; Cairns C; Hayes AC; Rahman M; Iqbal M; Haque A; Cox AD
J Immunol Methods; 2017 Nov; 450():27-33. PubMed ID: 28735760
[TBL] [Abstract][Full Text] [Related]
9. Mice vaccinated with the O-antigen of Francisella tularensis LVS lipopolysaccharide conjugated to bovine serum albumin develop varying degrees of protective immunity against systemic or aerosol challenge with virulent type A and type B strains of the pathogen.
Conlan JW; Shen H; Webb A; Perry MB
Vaccine; 2002 Oct; 20(29-30):3465-71. PubMed ID: 12297391
[TBL] [Abstract][Full Text] [Related]
10. Recent developments in bacterial protein glycan coupling technology and glycoconjugate vaccine design.
Terra VS; Mills DC; Yates LE; Abouelhadid S; Cuccui J; Wren BW
J Med Microbiol; 2012 Jul; 61(Pt 7):919-926. PubMed ID: 22516134
[TBL] [Abstract][Full Text] [Related]
11. Identification of Francisella tularensis outer membrane protein A (FopA) as a protective antigen for tularemia.
Hickey AJ; Hazlett KR; Kirimanjeswara GS; Metzger DW
Vaccine; 2011 Sep; 29(40):6941-7. PubMed ID: 21803089
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of Francisella tularensis ΔpdpC as a candidate live attenuated vaccine against respiratory challenge by a virulent SCHU P9 strain of Francisella tularensis in a C57BL/6J mouse model.
Tian D; Uda A; Park ES; Hotta A; Fujita O; Yamada A; Hirayama K; Hotta K; Koyama Y; Azaki M; Morikawa S
Microbiol Immunol; 2018 Jan; 62(1):24-33. PubMed ID: 29171073
[TBL] [Abstract][Full Text] [Related]
13. Genetic modification of the O-polysaccharide of Francisella tularensis results in an avirulent live attenuated vaccine.
Kim TH; Pinkham JT; Heninger SJ; Chalabaev S; Kasper DL
J Infect Dis; 2012 Apr; 205(7):1056-65. PubMed ID: 21969334
[TBL] [Abstract][Full Text] [Related]
14. Cloning, expression and characterization of recombinant exotoxin A-flagellin fusion protein as a new vaccine candidate against Pseudomonas aeruginosa infections.
Tanomand A; Farajnia S; Najar Peerayeh S; Majidi J
Iran Biomed J; 2013; 17(1):1-7. PubMed ID: 23279828
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity and safety of a tetravalent E. coli O-antigen bioconjugate vaccine in animal models.
van den Dobbelsteen GPJM; Faé KC; Serroyen J; van den Nieuwenhof IM; Braun M; Haeuptle MA; Sirena D; Schneider J; Alaimo C; Lipowsky G; Gambillara-Fonck V; Wacker M; Poolman JT
Vaccine; 2016 Jul; 34(35):4152-4160. PubMed ID: 27395567
[TBL] [Abstract][Full Text] [Related]
16. Genetic engineering of Francisella tularensis LVS for use as a novel live vaccine platform against Pseudomonas aeruginosa infections.
Robinson CM; Kobe BN; Schmitt DM; Phair B; Gilson T; Jung JY; Roberts L; Liao J; Camerlengo C; Chang B; Davis M; Figurski L; Sindeldecker D; Horzempa J
Bioengineered; 2015; 6(2):82-8. PubMed ID: 25617059
[TBL] [Abstract][Full Text] [Related]
17. A ΔclpB mutant of Francisella tularensis subspecies holarctica strain, FSC200, is a more effective live vaccine than F. tularensis LVS in a mouse respiratory challenge model of tularemia.
Golovliov I; Twine SM; Shen H; Sjostedt A; Conlan W
PLoS One; 2013; 8(11):e78671. PubMed ID: 24236032
[TBL] [Abstract][Full Text] [Related]
18. Intranasal administration of a two-dose adjuvanted multi-antigen TMV-subunit conjugate vaccine fully protects mice against Francisella tularensis LVS challenge.
McCormick AA; Shakeel A; Yi C; Kaur H; Mansour AM; Bakshi CS
PLoS One; 2018; 13(4):e0194614. PubMed ID: 29684046
[TBL] [Abstract][Full Text] [Related]
19. BALB/c mice, but not C57BL/6 mice immunized with a ΔclpB mutant of Francisella tularensis subspecies tularensis are protected against respiratory challenge with wild-type bacteria: association of protection with post-vaccination and post-challenge immune responses.
Twine S; Shen H; Harris G; Chen W; Sjostedt A; Ryden P; Conlan W
Vaccine; 2012 May; 30(24):3634-45. PubMed ID: 22484348
[TBL] [Abstract][Full Text] [Related]
20. Production of glycoprotein vaccines in Escherichia coli.
Ihssen J; Kowarik M; Dilettoso S; Tanner C; Wacker M; Thöny-Meyer L
Microb Cell Fact; 2010 Aug; 9():61. PubMed ID: 20701771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
